[Form 3] ASCENTAGE PHARMA GROUP INTERNATIONAL Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director Simon Dazhong Lu reports existing equity awards, not new trades. He holds stock options linked to 53,895 Ordinary Shares with an exercise price of 8.1400 per share, expiring on November 26, 2035, vesting in four equal parts from November 26, 2026 through 2029. He also holds restricted stock units covering 63,895 Ordinary Shares, vesting in the same four annual installments and with no expiration date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lu Simon Dazhong

Role Director

Type	Security	Shares	Price	Value
holding	Options	--	--	--
holding	Restricted stock units	--	--	--

Holdings After Transaction: Options — 53,895 shares (Direct); Restricted stock units — 63,895 shares (Direct)

Footnotes (1)

1. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lu Simon Dazhong

(Last) (First) (Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	11/26/2035	Ordinary Shares	53,895	$8.14(2)	D
Restricted stock units	(3)	(3)	Ordinary Shares	63,895	$0	D

Explanation of Responses:

1. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.

Remarks:

	Simon Dazhong Lu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position does Lu Simon Dazhong report at ASCENTAGE PHARMA (AAPG)?

Lu Simon Dazhong, a director of ASCENTAGE PHARMA, reports existing option and restricted stock unit holdings. This Form 3 establishes his baseline equity position as an insider, without showing any new purchases, sales, or exercises in the reported period.

How many stock options does Lu hold in ASCENTAGE PHARMA (AAPG) and on what terms?

Lu holds options linked to 53,895 Ordinary Shares with an exercise price of 8.1400 per share. The options vest in four equal installments on November 26 of 2026, 2027, 2028, and 2029, and expire on November 26, 2035 if not exercised.

What restricted stock units does Lu hold in ASCENTAGE PHARMA (AAPG)?

Lu holds restricted stock units covering 63,895 Ordinary Shares of ASCENTAGE PHARMA. Each RSU represents a contingent right to one Ordinary Share and vests in four equal annual installments from November 26, 2026 through 2029, with no stated expiration date.

Are Lu’s equity awards in ASCENTAGE PHARMA (AAPG) immediately vested?

No, Lu’s reported equity awards are subject to time-based vesting. Both the stock options and restricted stock units vest in four equal annual increments on November 26 of 2026, 2027, 2028, and 2029, meaning full vesting occurs only after the final date.

In what currency is the stock option exercise price for ASCENTAGE PHARMA (AAPG) set?

The stock option exercise price is set in Hong Kong dollars, but the table shows a 8.1400 per share value converted to U.S. dollars. The conversion uses the exchange rate on the grant date, as explained in the accompanying footnote.